Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference on December 8, 2022, at 9:10 a.m. ET. The event aims to provide insights into the company's initiatives focused on genetically defined rare diseases. A live audio webcast will be accessible on the Fulcrum website, with an archived replay available for 30 days after the event. Fulcrum is advancing two key clinical programs: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET

A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on LinkedIn.

Contacts:

Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324

FAQ

What is the date and time of Fulcrum Therapeutics' participation in the BofA Securities Biotech SMID Cap Conference?

Fulcrum Therapeutics will participate in the conference on December 8, 2022, at 9:10 a.m. ET.

How can I access the live webcast of Fulcrum Therapeutics' presentation?

The live audio webcast can be found in the Investor Relations section of Fulcrum's website.

What are the lead clinical programs of Fulcrum Therapeutics?

Fulcrum's lead programs are losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

Will there be a replay available for Fulcrum Therapeutics' conference presentation?

Yes, an archived replay will be available on Fulcrum's website for 30 days after the event.

What is the focus of Fulcrum Therapeutics as a biopharmaceutical company?

Fulcrum Therapeutics focuses on improving the lives of patients with genetically defined rare diseases.